GE HealthCare stock heads toward a higher quarterly dividend

Published on 10/04/2026 at 21:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock was last at USD 64.29 on October 2, while second-quarter revenue reached USD 5.295 billion. A USD 0.04 dividend is due November 13.

Extreme Nahaufnahme einer grünen Leiterplatte mit goldenen Leiterbahnen in Medizingerät — GE HealthCare US36266G1076 zeigt Makro-Detail einer grünen Leiterplatte aus einem medizinischen Diagnosegerät, Illustration mit AI erstellt.

GE HealthCare stock was last at USD 64.29 on Nasdaq on October 2, 2026, up 0.48 percent from the previous close. The company is approaching a quarterly dividend of USD 0.04 per share after its board announced a 14 percent increase on September 22, 2026, according to Securities.io.

Dividend date brings a clear checkpoint

GE HealthCare Technologies declared the dividend for the third quarter of 2026, payable on November 13, 2026, to shareholders of record on October 23, 2026. The increase follows a prior quarterly payment of USD 0.035 per share, giving the capital return decision a concrete comparison.

The dividend arrives while the company works through a mixed operating picture. Patient Care Solutions revenue fell 13.3 percent in the second quarter, while Advanced Imaging Solutions revenue increased 7.9 percent and Pharmaceutical Diagnostics revenue rose 15.6 percent, according to Securities.io.

Second-quarter figures set the earnings base

For the quarter ended June 30, 2026, revenue reached USD 5.295 billion, up 5.7 percent year over year, while organic revenue growth was 3.5 percent. Net income attributable to GE HealthCare rose to USD 561 million from USD 486 million, and diluted EPS increased 16.5 percent to USD 1.24, according to Securities.io.

Orders provide the stronger operating counterweight: organic orders growth reached 11.1 percent and backlog stood at USD 23.9 billion in the same quarter. Full-year 2026 guidance called for organic revenue growth of 3.0 percent to 4.0 percent, adjusted EBIT margin of 15.4 percent to 15.7 percent and adjusted EPS of USD 4.80 to USD 5.00, with tariff refunds excluded from that outlook.

Analyst targets remain above the stock

CNBC reported on September 22, 2026, that Needham initiated coverage with a Buy rating and a USD 93 price target. The target lies 44.7 percent above the October 2 price of USD 64.29, making valuation and execution the central test for the bullish view.

MarketBeat reported a Moderate Buy consensus from 22 analysts, including 11 Buy and 11 Hold ratings, with an average price target of USD 78.39. That target lies 21.9 percent above the October 2 price, while the latest quarterly figures show why investors are weighing growth in imaging and diagnostics against weakness in Patient Care Solutions.

GE HealthCare stock stays below its yearly high

GE HealthCare stock was last at USD 64.29 on Nasdaq on October 2, 2026, with volume of 3,235,164 shares and a market capitalization of USD 29.0 billion. The USD 58.75 to USD 89.77 52-week range places the stock 28.4 percent below its yearly high.